HCPLive Network

Fred Poordad, MD, on Ethnic Differences in Telaprevir Treatment Effect

In this video Fred Poordad, MD, Chief of Hepatology and Liver Transplantation at the Comprehensive Transplant Center at Cedars-Sinai Medical Center evaluates the effect of race on the response to treatment and viral resistance profiles with telaprevir combination therapy.

 
Related Videos
Inflammatory bowel disease patients are already benefiting from technology advancements in healthcare, but there are barriers to providing care through telemedicine, Raymond Cross, MD.
Since pancreatic cancer is so rare, screening among the general population is not worthwhile, according to Randall Brand, MD. Instead, physicians should only screen those individuals considered "high risk."
Inflammatory bowel disease patients can benefit greatly from telemedicine, because physicians can interact more frequently with patients, according to Raymond Cross, MD.